Methods of measuring protein disulfide isomerase activity: a critical overview by Monica M. Watanabe et al.
MINI REVIEW ARTICLE
published: 03 September 2014
doi: 10.3389/fchem.2014.00073
Methods of measuring protein disulfide isomerase activity:
a critical overview
Monica M. Watanabe , Francisco R. M. Laurindo and Denise C. Fernandes*
Vascular Biology Laboratory, Heart Institute (InCor), University of São Paulo School of Medicine, São Paulo, Brazil
Edited by:
Bulent Mutus, University of
Windsor, Canada
Reviewed by:
Laura De Gara, Università Campus
Bio-Medico di Roma, Italy
Elia Ranzato, University of Piemonte
Orientale “Amedeo Avogadro”, Italy
*Correspondence:
Denise C. Fernandes, Vascular
Biology Laboratory, Heart Institute
(InCor), University of São Paulo
School of Medicine, Av Eneas C
Aguiar, 44, 9th floor, CEP
05403-000, São Paulo, Brazil
e-mail: denisef@usp.br
Protein disulfide isomerase is an essential redox chaperone from the endoplasmic
reticulum (ER) and is responsible for correct disulfide bond formation in nascent proteins.
PDI is also found in other cellular locations in the cell, particularly the cell surface. Overall,
PDI contributes to ER and global cell redox homeostasis and signaling. The knowledge
about PDI structure and function progressed substantially based on in vitro studies using
recombinant PDI and chimeric proteins. In these experimental scenarios, PDI reductase
and chaperone activities are readily approachable. In contrast, assays to measure PDI
isomerase activity, the hallmark of PDI family, are more complex. Assessment of PDI
roles in cells and tissues mainly relies on gain- or loss-of-function studies. However, there
is limited information regarding correlation of experimental readouts with the distinct
types of PDI activities. In this mini-review, we evaluate the main methods described for
measuring the different kinds of PDI activity: thiol reductase, thiol oxidase, thiol isomerase
and chaperone. We emphasize the need to use appropriate controls and the role of
critical interferents (e.g., detergent, presence of reducing agents). We also discuss the
translation of results from in vitro studies with purified recombinant PDI to cellular and
tissue samples, with critical comments on the interpretation of results.
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Protein disulfide isomerase is present in most eukaryotic
organisms and is an essential redox chaperone that catalyzes
the introduction of disulfide bonds and the rearrangement of
incorrect ones in nascent proteins into the endoplasmic retic-
ulum lumen. PDI was the first protein with folding activity
described in the literature (Goldberger et al., 1964), and is the
founder of the mammalian PDI family. Currently there are 20 or
more other PDI members containing one or more thioredoxin-
like domains (Lu and Holmgren, 2014). PDI is formed by four
thioredoxin-like structural domains, two of them containing the
CGHC (cysteine-glycine-histidine-cysteine) catalytic motif capa-
ble of catalyzing sulfydryl oxidation and reduction/isomerization
of disulfide bonds (for a revision see Hatahet and Ruddock,
2009). The two other domains form a central hydrophobic core
pocket involved in substrate binding. A mobile arm close to
the C-terminal site regulates, on a redox-dependent way, sub-
strate access to the hydrophobic core (Wang et al., 2013). In
addition to its role in disulfide introduction in nascent pro-
teins, PDI has a chaperone effect, preventing protein aggregation
in a way not directly related to its redox thiols, but rather to
the hydrophobic pocket region away from the redox domains.
PDI binds in vitro to a variety of molecules, from small pep-
tides to proteins, while in vivo only a few client proteins were
identified (Hatahet and Ruddock, 2009). In plasma membrane
and pericellular compartments, PDI is involved in important
biological processes such as thrombus formation, tissue factor
regulation, platelet aggregation, cell adhesion and virus internal-
ization. The multiple PDI cellular redox effects and its versatility
in binding to several proteins implicate that PDI may act as an
emerging redox cell signaling adaptor (Laurindo et al., 2012)
and a promising therapeutic target of several diseases (Xu et al.,
2014).
There are several assays to measure PDI activity. Some assays
are more specific to one particular PDI activity (e.g., thiol reduc-
tion or oxidation), while others focus in the measurement of PDI
isomerase activity. Methods for PDI activity in general are used
for 3 main purposes: (a) the study of protein folding by PDI to
identify substrate intermediates, which requires elaborated analy-
sis and detection by mass spectroscopy, (b) screening of PDI sub-
strates or inhibitors, which demands fast and low-cost assays to be
preferentially adopted for high-throughput system (HTPS) plat-
forms, (c) understanding PDI function in (patho)physiological
contexts by comparison of PDI activities in different experimental
conditions in biological samples. Proteins such as bovine pan-
creatic tripsin inhibitor (BPTI) and ribonuclease T1 (RNaseT1)
fit the requirements for studies of PDI-mediated protein folding,
while insulin has been chosen for HTPS automation. However,
PDI assays in biological samples are a considerable challenge.
Some substrates commonly used for purified PDI assays (insulin
or fluorescent GSSG) were already used in cell homogenates, but
the interpretation is still difficult due to intrinsic interferents such
as the presence of other reductants in the assay. The purpose
of this review is to critically discuss the most used methods of
measuring the different types of PDI activities (e.g., isomerase,
oxidative refolding, reductase, and chaperone), with emphasis
given to PDI in biological samples.
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AN OVERVIEW OF PDI ACTIVITY ASSAYS
Depending on the starting material, i.e., the “substrate” of PDI,
one PDI activity will be preferentially measured over others.
Therefore, PDI assays can be classified based on the initial redox
state of the substrate. When the substrate of a protein contains
scrambled disulfides and PDI catalyzes its conversion to native
state (and thus the recovery of substrate activity), this assay is
named “isomerase assay” (e.g., scrambled RNase isomerization).
In the case of a totally reduced protein, PDI will promote “oxida-
tive refolding” in a series of thiol oxidation/reduction cycles and
possibly isomerization reactions to promote substrate gain-of-
function (e.g., reduced RNase oxidative folding). PDI reductase
activity assays are easier to perform and constitute the most pop-
ular in the literature. According to substrate, reductase activity
is followed through increase in turbidity or fluorescence changes
(e.g., insulin reduction). Finally, using proteins that do not con-
tain disulfide bonds as substrates, PDI chaperone activity can
be measured by recovery of substrate activity and/or changes in
substrate protein aggregation (e.g., GAPDH aggregation).
When developing a PDI assay, it is important to keep in
mind that PDI does not have a known preferential group of
substrates (such as Erp57, that preferentially folds glycosylated
proteins, Jessop et al., 2007) and substrates used in PDI assays
were not so far proven to be physiological PDI substrates. Also,
PDI concentration at ER lumen is estimated around 0.2–0.5mM
(Lyles and Gilbert, 1991), so PDI would be in excess over many
substrates, a condition that is not generally mimicked in these
assays. Many in vivo conditions are not considered in such
PDI reductase activity assays: PDI cellular compartmentalization,
molecular crowding inside cells (which affects protein folding
stability, Zhou, 2013), and PDI recycling after substrate folding—
promoted by PDI partners (e.g., endoplasmic reticulum oxidase-
Ero1, Rancy and Thorpe, 2008 or oxidized peroxiredoxin-Prx4,
Zito et al., 2010). Finally, another important issue is that although
in vitro PDI chaperone and isomerase activities can be mea-
sured separately, in vivo PDI redox folding will not discriminate
between both activities and, contrarily, seems to require iso-
merase and chaperone activities acting together (Laurindo et al.,
2012). Thus, results obtained from in vitro assays should also be
interpreted taking into account their limitations due to a reduc-
tionist design. A way to partially overcome such limitations is
to preferentially combine the measurement of PDI activity with
in vivo data and discuss them in the context of the specific
physiological milieu being investigated.
ISOMERASE ASSAY
Assays for isomerase activity are based on gain-of-function of
an inactive protein substrate containing unfolded disulfides (or
scrambled disulfide bonds), so it is inactive. In the presence of
PDI, disulfides bonds will be folded back to a “correct” position,
thus allowing the measurement of activity of the recovered sub-
strate. Two enzymes are more commonly used, scrambled RNase
(scRNase, 4 disulfides) and riboflavin-binding protein (RfBP, 9
disulfides).
For RNase, which is reduced in denaturing conditions and
then allowed to oxidize under air at room temperature to acquire
random disulfide bonds (Figure 1), aliquots are removed to mea-
sure substrate activity recovery during incubation with PDI.
Partial folded RNAse can be quenched with excess alkylating
agent before measuring RNAse activity recovery (Rancy and
FIGURE 1 | Scheme of some PDI activity assays. (A) RNase with
scrambled thiols can be used as initial substrate for PDI isomerase
assay, while totally reduced RNAse is used for PDI-mediated oxidative
refolding assay. RNase gain-of-activity is measured by hydrolysis of its
substrates, namely RNA or cyclic CMP. (B) Peptides can be used for
oxidase, reductase or isomerase PDI assays, based on energy transfer
from a donor to an acceptor residue with changes in fluorescence
intensity. (C) PDI reduction assay is usually performed with insulin as
substrate, which precipitates upon reduction of its B chain thiols.
Coupling insulin reduction with NADPH consumption (using thioredoxin or
glutaredoxin reductase systems) provides more precise quantitative
results. See text for details.
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Thorpe, 2008), which is measured following the hydrolysis of 2
different RNAse substrates: high-molecular-weight RNA (Hillson
et al., 1984) or cyclic cytidine monophosphate (cCMP) (El Hindy
et al., 2014). The second provides higher increases in absorbance,
but requires correction due to cCMP depletion over time and
CMP-mediated RNase inhibition (Lyles and Gilbert, 1991). The
assay buffer generally contains the redox pair GSH/GSSG, to
drive PDI catalysis. One disadvantage of this method is that the
most desirable is to obtain all experimental results from the same
scRNase batch due to heterogeneity of scRNase among prepa-
rations. Otherwise, it is difficult to have reproducible results,
independently if scRNase is home-made or commercial (Hatahet
and Ruddock, 2009). This method has been extensively used in
mechanistic PDI studies. It can also be applied in some particu-
lar cellular preparations, such as enriched-membrane fraction of
vascular cells (Janiszewski et al., 2005) which does not contain sol-
uble thioredoxin or glutaredoxin reductase systems, and thus may
preferentially reflect PDI activity. Of note, it is important to con-
firm the presence of PDI in the analyzed specimen using western
blotting (and even to use the amount of protein to normalize the
activity).
The assay with RfBP is based on fluorescence quenching of
free riboflavin due to its binding to apoRfBP (RfBP previously
reduced under denaturing conditions to release riboflavin, fol-
lowed by ferricyanide oxidation) (Rancy and Thorpe, 2008).
ApoRfBP is mixed with riboflavin in the presence of PDI, and
riboflavin fluorescence is measured directly. It is potentially a
powerful assay, in which PDI is used in excess over substrate (30-
fold), but is not a measurement of gain-of-function (Hatahet and
Ruddock, 2009). This assay was not tested with biological sam-
ples yet. In homogenate samples the concentration of reagents
would have to be optimized, in order to minimize the fluores-
cence interference of endogenous flavoenzymes, and secondarily,
the interference of endogenous riboflavin binding proteins, such
as riboflavin kinase or riboflavin transporters. This assay is not
recommended for samples, such as plasma, with high levels of
albumin or immunoglobulins (which also bind riboflavin).
OXIDATIVE REFOLDING ASSAY
Several fully reduced proteins can be used as substrates for PDI
mediated-oxidative refolding. RNase and BPTI (3 disulfides) are
considered the best model substrates of oxidative folding assay.
In both cases, the intermediates formed during PDI-mediated
oxidative folding are characterized by mass spectroscopy after
thiol alkylation (Irvine et al., 2014). Although time-consuming,
this experimental strategy is the best to estimate rate constants
of PDI-dependent reactions during different steps of the fold-
ing process (Hatahet and Ruddock, 2009). Other frequently-
used substrates include: lysozyme (4 disulfides, van den Berg
et al., 1999) and 2 modified RNases, RNaseT1 (2 disulfides)
and glutathionylated RNAseT1 (Ruoppolo and Freedman, 1995;
Ruoppolo et al., 1996). Reduced RNaseT1 behaves in the assay as
reduced RNase, while the glutathionylated substrate has to be deg-
lutathionylated in the first step, a step that may also be mediated
by PDI (Reinhardt et al., 2008; Townsend et al., 2009). Translation
of oxidative refolding assays to biological samples has the same
difficulties as those of isomerase activity discussed previously.
REDUCTION ASSAY
In this assay, PDI will reduce disulfides bonds present in the
oxidized substrate. The most popular substrate, due to techni-
cal simplicity and low cost, is insulin. The reduction of insulin
promotes the aggregation of insulin B chain and is followed by
increase in turbidity. PDI is incubated with freshly prepared clear
insulin solution in the presence of a reducing agent (DTT or
GSH) (Holmgren, 1979). Better aggregation curves are obtained
with B chain of insulin than A chain, which induces high back-
ground readouts (Karala and Ruddock, 2010). The kinetics of
insulin reduction generates two parameters that can be used for
relative quantification of different catalysts: the lag time (the
time that takes to start precipitation, which can be set as an
increase by 0.02 in absorbance over the baseline) and the rate
of precipitation (the maximal absorbance increase per minute,
absorbance × min−1). It is the method elected for screening
PDI inhibitors in diverse experimental setups (Khan et al., 2011;
Paes et al., 2011; Jasuja et al., 2012), and can be optimized for
HTPS (Smith et al., 2004) or coupled to fluorogenic dye in com-
mercial kits (ProteoStat™ PDI Assay Kit from Enzo Life Sciences
and PDI Inhibitor Screening Assay Kit from AbCam). It was also
used in cellular homogenates. To increase assay sensitivity, flu-
orescent insulin (FITC-insulin) can be used. Also, in order to
improve assay quantification, it is also possible to couple insulin
reduction with NADPH consumption by coupling with GSSG (or
thioredoxin reductase, Figure 1). In this case, one enzyme unit
is defined as the amount of PDI that catalyzes the formation of
GSSG per min, and kinetic parameters can be quantified (Vmax,
Kobs, Ki). The assay has to be optimized in a way that insulin
aggregation does not interfere with NADPH absorbance (e.g.,
340 nm) (Morjana and Gilbert, 1991; Lee et al., 2014).
Other compound used for PDI reduction assay is GSSG.
Although GSSG is a poor substrate for PDI (Hatahet and
Ruddock, 2009), GSSG covalently attached to eosin (Di-E-GSSG)
provides a good sensitivity to the assay, able to detect around nM
PDI (Raturi and Mutus, 2007). Di-E-GSSG is non-fluorescent
due to self-quenching of two proximal eosin moieties, but after
reduction the probe shows ∼70-fold increase in fluorescence.
This method has been already used for biological samples, such as
endothelial cell (HMEC-1) homogenates (Muller et al., 2013) and
plasma (Prado et al., 2013). Finally, there is a radioactive method
in which the release of radioactive I125-tyramine-SH is assessed,
using I125-tyramine-SS-poly-(D-lysine) as substrate, bound to
anionic cell surface. This method was employed in intact cells
(myeloid and erythrocytes) to measure cell surface PDI reduc-
tase activity (Gallina et al., 2002), although confounding effects
can potentially occur due to activity of proteases able to cleave the
substrate (Xu et al., 2014).
PEPTIDES AS PDI SUBSTRATES
Some peptides have been developed to measure PDI activities
in vitro and might have promising results when tested in biolog-
ical samples. Peptides linked to fluorescent moieties allow high
sensitivity and direct measurement of fluorescence. One example
is a peptide based on tachyplesin I (TI), a 17-residue antimicrobial
peptide that crossesmembranes (Kersteen et al., 2005). Scrambled
TI (4 cysteines) is isomerized by PDI to its native conformation
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in which a tryptophan and a dansyl-linked lysine physically inter-
act, allowing fluorescence resonance energy transference (FRET).
Another peptide, which can be used for reduction or oxidation
PDI assays, depending on initial peptide redox state, contains two
cysteines separated by a non-aethyleneglycol spacer (Christiansen
et al., 2004). When reduced, this peptide is fluorescent due to
o-aminobenzoyl group in theN-terminal region. Upon oxidation,
o-aminobenzoyl fluorescence is quenched due to proximity with
nitrotyrosine in the C-terminal segment. As a control, a peptide in
which a cysteine is changed to serine can be used. Although they
are not commercially available, both peptides show the advan-
tages of enhanced homogeneity as starting materials (compared
to scrambled thiol-proteins) and direct measurement of peptide
fluorescence (i.e., aminobenzoyl/dansyl groups) within samples.
CHAPERONE ASSAY
Assays for chaperone-like activity of PDI are based on the cataly-
sis by PDI of the self-refolding process of completely denatured
substrates, which does not require disulfide bonds for folding.
The first method for chaperone-like PDI activity was proposed
to distinguish PDI chaperone from disulfide isomerase activity,
using D-glyceraldehyde-3-phosphate dehydrogenase as substrate
(Cai et al., 1994). Other substrates that can be used are lac-
tate dehydrogenase, chemically denatured-rhodanese or citrate
synthase, and thermally denatured-alcohol dehydrogenase (Xu
et al., 2014). Briefly, the denatured protein is diluted in refold-
ing buffer, in the presence of excess PDI (5–10-fold) and changes
in aggregation are followed by light scattering or turbidity. Since
changes in aggregation may not correlate with efficient substrate
gain-of-function, many authors also measure the reactivation of
the substrate, which requires the dissociation of PDI: substrate
complex and optimization of substrate reactivation assay. One
recently-reported assay uses green fluorescent protein as PDI sub-
strate to increase sensitivity (Mares et al., 2011). However, it is
important to note that oxidation can switch PDI conformation
and interfere with its chaperone function (Wang et al., 2013).
CRITICAL COMMENTS ON THE MEASUREMENT OF PDI
ACTIVITY IN BIOLOGICAL SAMPLES
All the assays discussed above can be, in theory, applied to bio-
logical samples since in general the latter contain high amounts
of PDI. With the combination of specific PDI inhibitors, one may
guarantee that the activity measured in the whole homogenates is
in fact due to PDI and not to other reductase or reduction sys-
tems. However, in practice it not as simple as that. Indeed, so
far only reductase assays were reportedly transposed to cellular
samples. Measurement of reductase PDI activity in cell surface
is less prone to endogenous interferents, and the assay can be
combined with a neutralizing PDI antibody (Raturi and Mutus,
2007; Langer et al., 2013). In whole cell homogenates, reduc-
tase assays will be affected by other reductase systems such as
thioredoxin or glutaredoxin. Indeed, the fluorescent Di-E-GSSG
was recently employed to measure thioredoxin reductase activ-
ity in serum, plasma and lymphocyte lysate (Montano et al.,
2014). Furthermore, biological samples might have endogenous
unknown PDI inhibitors, as suggested by the observations from
our laboratory indicating higher lag time for insulin reduction
when exogenous PDI is incubated together with homogenates, as
compared to exogenous PDI alone (Figure 2A). These observa-
tions reinforce the use of a panel of PDI inhibitors and/or the
strategy of PDI gain/loss-of-function to provide reliable results
for PDI activity assays. For example, in endothelial cells PDI
FIGURE 2 | Spurious inhibitors and detergents as PDI reductase assay
interferents in biological samples. (A) PDI overexpression (∼3-fold increase
vs. endogenous PDI) increased, while PDI silencing (by ca.70%) did not
change insulin reduction in endothelial cell homogenates. Freshly prepared
homogenates (150µg) obtained by mechanical lysis (in the absence of
detergents) were incubated with insulin (1mg/mL) and PDI (1.5µM) in the
presence of DTT (1.5mM) and insulin turbidity was assessed at 540nm. pPDI
= purified PDI, mock = cells treated with transfection reagent, wtPDI = cells
transfected with wild type PDI, siRNA = cells transfected with siRNA against
PDI. Cells were lysed 24h after transfection procedure. Note the higher lag
time for insulin reduction when exogenous PDI is incubated together with
homogenates (mock), as compared with exogenous PDI alone (pPDI),
suggesting that biological samples might have endogenous unknown PDI
inhibitors. (B) Detergents commonly used in buffers in different experimental
protocols can inhibit or increase insulin reduction mediated by PDI in vitro,
depending on their concentration. PDI (1.5µM) was incubated with insulin at
the same experimental conditions of (A). Detergents (nonionic Triton X-100,
anionic sodium dodecyl sulfate or anionic sodium deoxycholate) were added at
concentrations 100-fold (150µM) to 0.1-fold (0.15µM) vs. PDI concentration.
Lag time was calculated as time for absorbance reaching 0.1 unit.
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reductase activity was increased by 2-fold after overexpression
of wild-type PDI, while no such increase was detected in cells
overexpressing PDI mutated in all redox thiols (Muller et al.,
2013). Using the coupled insulin reduction assay, Lee et al. (2014)
showed that overexpression of both PDI and thioredoxin inter-
action protein (Txnip) increased NADPH consumption in cell
homogenates compared to PDI transfected controls. In vascular
cells, PDI overexpression decreased the lag time of insulin reduc-
tion kinetics, although PDI silencing had no effect (Figure 2A).
These data also suggest that in complex samples, results obtained
with PDI reduction assays might significantly reflect PDI expres-
sion levels rather than “intrinsic” PDI isomerase activity within
cell. One possible alternative is to measure PDI activity after
its immunoprecipitation, which reduces contaminants from the
whole homogenate.
Several molecules are known to bind and inhibit PDI activity
in vitro (e.g., nitric oxide, the hormones T3 and estrogen, the pep-
tides somastotin and bacitracin, synthetic organic compounds as
bisphenol A and phenylarsenic oxide). However, only few are able
to inhibit PDI in some particular experimental in vivo conditions.
Examples are the reversible PDI inhibitors derived from plants,
juniferdin (Khan et al., 2011) and quercetin-3-rutinoside (Jasuja
et al., 2012), as well as synthetic compounds that irreversibly
inhibit PDI, 16F16, thiomuscimol (Hoffstrom et al., 2010), RB-
11-ca (Banerjee et al., 2013), and PACMA31(Xu et al., 2012).
These compounds may be used as additional controls during PDI
activity assays, although none of these compounds to date have
been shown to specifically inhibit PDI. The neutralizing anti-PDI
(RL90) antibody is also a powerful control through its specificity,
although recently Wu et al. (2012) showed some cross-reactivity
with another member of PDI family, Erp57, in Di-E-SSG assay.
Another important experimental topic is the buffer used for
cell and tissue lysis. In general they contain, in addition to reduc-
ing agents, one or more surfactants, necessary for cell membrane
rupture. For example, the widely used RIPA lysis buffer con-
tains NP-40 (1%, 16mM), sodium deoxycholate (0.5%, 12mM)
and sodium dodecyl sulfate (0.1%, 3.5mM) (Cold Spring Harbor
Protocols). However, Triton was already shown to bind PDI b’
domain and strongly inhibit enzyme activity (Klappa et al., 1998),
and is typically used at 0.05% (0.77mM) to inhibit purified
PDI in reduction assay (Karala and Ruddock, 2010). Indeed,
results from our laboratory indicate that surfactants with dis-
tinct physicochemical properties significantly alter PDI reductase
activity in vitro (Figure 2B, same for NP40, CHAPS and saponin).
Inhibition or even a small increase of PDI-mediated insulin
reduction depends on the proportion between PDI and deter-
gent molecules (Figure 2B). Thus, the best procedure for PDI
activity assays is to obtain protein extracts by mechanical lysis in
detergent-free buffers.
CONCLUSIONS AND PERSPECTIVES
Understanding the role of PDI in cells and tissues as a homeostatic
redox signaling adaptor with chaperone properties will require
different assays to assess PDI activity. Currently, a major chal-
lenge is to precisely measure overall PDI isomerase activity in cells
and tissues, and not only one step of thiol rearrangement (oxida-
tion or reduction). In addition, the assay should be performed
preferentially in situ, since PDI activity may change depending on
cell location or redox status. As long as the ideal PDI isomerase
assay is yet unavailable for cells and tissues, PDI reductase activity
has been measured instead in the cell surface and intact cells, as
well as cell homogenates. Such results should be interpreted with
care. Improvements in assay reliability will probably require not
only advances into sensitivity and specificity, but optimization of
adequate controls as well (neutralizing PDI antibodies or more
specific emerging PDI inhibitors), or even cell fractionation to
remove other reductase systems. Optimization of assays with fluo-
rescent peptides for biological samples seems to be a forthcoming
promising approach.
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